Related references
Note: Only part of the references are listed.Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
Linlin Ma et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis
Xin You et al.
CANCER COMMUNICATIONS (2019)
Disrupting CD47-SIRP alpha axis alone or combined with autophagy depletion for the therapy of glioblastoma
Xuyao Zhang et al.
CARCINOGENESIS (2018)
MIR-708 promotes phagocytosis to eradicate T-ALL cells by targeting CD47
Wei Huang et al.
MOLECULAR CANCER (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer
Alex D. Michaels et al.
CLINICAL CANCER RESEARCH (2018)
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
Hanke L. Matlung et al.
IMMUNOLOGICAL REVIEWS (2017)
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
Jun Chen et al.
NATURE (2017)
Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
E. C. Pietsch et al.
BLOOD CANCER JOURNAL (2017)
Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells
Liang Liu et al.
FRONTIERS IN IMMUNOLOGY (2017)
Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia
Bas J. Wouters et al.
BLOOD (2016)
An update of current treatments for adult acute myeloid leukemia
Herve Dombret et al.
BLOOD (2016)
Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma
Jessica Lo et al.
LIVER INTERNATIONAL (2016)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Zhenyu Xiao et al.
CANCER LETTERS (2015)
Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 Don't Eat Me Signals
Melissa N. McCracken et al.
CLINICAL CANCER RESEARCH (2015)
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Emily C. Piccione et al.
MABS (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
A. Neil Barclay et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis
Yuhua Wang et al.
MOLECULAR THERAPY (2013)
Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells
Mahban Irandoust et al.
PLOS ONE (2013)
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest
E. Sick et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
D. Kim et al.
LEUKEMIA (2012)
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy
Mark P. Chao et al.
BLOOD (2011)
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Mark P. Chao et al.
CANCER RESEARCH (2011)
A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1α pathway
Morihiko Sagawa et al.
CANCER SCIENCE (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
Mark P. Chao et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Share Paper
